Table 2

Association between PA (measured in both total MET-min/week and overall 7-day average acceleration) and maximal NC/C ratio for both the dose–response and extreme groups analysis

Clinical cardiac parameter	PA measurement method	Model
		Unadjusted			Limited adjustment			Full adjustment
		Effect Estimate	95% CI	P value	Effect Estimate	95% CI	P value	Effect Estimate	95% CI	P value
Dose–response analysis	Total MET-min/week	0.019	−0.019 to 0.056	0.32	0.024	−0.013 to 0.060	0.20	−0.001	−0.039 to 0.037	0.97
Dose–response analysis	Seven-day average acceleration	−0.012	−0.062 to 0.039	0.65	−0.007	−0.059 to 0.045	0.79	−0.047	−0.110 to 0.015	0.13
Extreme groups analysis	Total MET-min/week	0.049	−0.060 to 0.158	0.38	0.062	−0.046 to 0.171	0.26	−0.026	−0.146 to 0.094	0.67
Extreme groups analysis	Seven-day average acceleration	−0.036	−0.157 to 0.086	0.56	−0.017	−0.144 to 0.111	0.79	−0.129	−0.299 to 0.040	0.49

Effect estimate reflects an NC/C ratio change per IQR of either total MET-min/week or 7-day average acceleration.
MET, metabolic equivalent of task; NC/C, non-compaction/compaction; PA, physical activity.